drugset / Trial / NCT06480461
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
A phase Ⅰ/Ⅱ study to evaluate the tolerability, safety, and efficacy of VGN-R09b in pa-tients with Parkinson's disease
Timeline
- Start
- 2024-09-02
- Primary completion
- 2026-09-10
- Completion
- 2030-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VGN-R09b | Gene therapy (AAV / viral vector) | 8e+11 vg | — |
| Subject | VGN-R09b | Gene therapy (AAV / viral vector) | 1.6e+12 vg | — |
| Subject | VGN-R09b | Gene therapy (AAV / viral vector) | 3.2e+12 vg | — |